In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

JPMorgan (NYSE:JPM) analysts lowered their rating for Nio (NYSE:NIO) to Neutral from Overweight in a note Tuesday, citing concerns over earnings delivery and a more conservative outlook compared to ...